Regulation of cell migration and invasion by specific modules of uPA: Mechanistic insights and specific inhibitors

Current Drug Targets

Volumn 12, Issue 12, 2011, Pages 1761-1771

  Carriero, Maria Vincenza ^a   Franco, Paola ^b   Votta, Giuseppina ^b   Longanesi Cattani, Immacolata ^a   Vento, Maria Teresa ^b   Masucci, Maria Teresa ^a   Mancini, Alessandro ^c   Caputi, Mario ^c   Iaccarino, Ingram ^b   Stoppelli, Maria Patrizia ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cell invasion; Cell migration; Inhibitors of cell invasion; Inhibitors of cell migration; Peptides; Urokinase

Indexed keywords

BENZYLSULFONYL DEXTRO SERINE SERINE 4 AMIDINOBENZYLAMIDE; CELECOXIB; CISPLATIN; EPIDERMAL GROWTH FACTOR; FP 59; G PROTEIN COUPLED RECEPTOR; GEMCITABINE; INTEGRIN; MATRIX METALLOPROTEINASE; MUPAIN 1; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C INHIBITOR; PROTEINASE; SCATTER FACTOR; TISSUE PLASMINOGEN ACTIVATOR; UK 122; ULINASTATIN; UNCLASSIFIED DRUG; UPAIN 1; UROKINASE; UROKINASE RECEPTOR; WX 671; WX UK1;

ANGIOGENESIS; BREAST CARCINOMA; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DIABETIC MACULAR EDEMA; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; FIBROSARCOMA; GLIOBLASTOMA; HUMAN; KRINGLE DOMAIN; LUNG CARCINOMA; LUNG METASTASIS; METASTASIS; NONHUMAN; OVARY CARCINOMA; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CELL MOVEMENT; HUMANS; KRINGLES; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATORS; PROTEIN INTERACTION DOMAINS AND MOTIFS; SERINE PROTEINASE INHIBITORS; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 80051703869     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011797635777     Document Type: Review

References (99)

1. Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: integrating signals from front to back. Science 2003; 302: 1704-9.
2. Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol 2010; 11: 633-43.
3. Le Y, Yang Y, Cui Y, et al. Receptors for chemotactic formyl peptides as pharmacological targets. Int Immunopharmacol 2002; 2: 1-13.
4. Chung HJ, Park TG. Surface engineered and drug releasing pre- fabricated scaffolds for tissue engineering. Adv Drug Deliv Rev 2007; 59: 249-62.
5. Heisenberg CP, Solnica-Krezel L. Back and forth between cell fate specification and movement during vertebrate gastrulation. Curr Opin Genet Dev 2008; 18: 311-6.
6. Iwamoto T, Okamoto H, Toyama Y, Momohara S. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J 2008; 275: 4448-55.
7. Steeg PS. Tumour metastasis: mechanistic insights and clinical challenges. Nature Med 2006; 12: 895-904.
8. Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-84.
9. Irigoyen JP, Muñoz-Cánoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999; 56: 104-32.
10. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase- type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22.
11. Johanna AJ, Jeffrey W. Pollard Microenvironmental regulation of metastasis. Nat Rev Cancer 2008; 9: 239-52.
12. Lund LR, Romer J, Bugge TH, et al. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 1999; 18: 4645-56.
13. Holst-Hansen C, Low JA, Stephens RW, et al. Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat. Breast Cancer Res Treat 2001; 68: 225-37.
14. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumour growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
15. Binder BR, Mihaly J. The plasminogen activator inhibitor paradox in cancer. Immunol Lett 2008; 118: 116-24.
16. Blasi F, Carmeliet P. uPAR: a versatile signaling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-43.
17. Alfano D, Iaccarino I, Stoppelli MP. Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J Biol Chem 2006; 28: 17758-67.
18. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007; 97: 336-42.
19. Bifulco K, Longanesi-Cattani I, Gala M, et al. The soluble form of urokinase receptor promotes angiogenesis through its SER(88)- ARG-SER-ARG-TYR(92) chemotactic sequence. J Thromb Haemost 2010; 8: 2789-99.
20. Conn EM, Botkjaer KA, Kupriyanova TA, Andreasen PA, Deryugina EI, Quigley JP. Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion. Am J Pathol 2009; 175: 1638-52.
21. Shapiro RL, Duquette JG, Roses DF, et al. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 1996; 56: 3597-604.
22. Bugge TH, Kombrinck KW, Xiao Q, et al. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood 1997; 90: 4522-31.
23. Frandsen TL, Holst-Hansen C, Nielsen BS, et al. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Res 2001; 6: 532-7.
24. Almholt K, Lund LR, Rygaard J, et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 2005; 113: 525-32.
25. Schmitt M, Jänicke F, Graeff H. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul Fibrinolysis 1990; 1: 695-702.
26. Del Vecchio S, Stoppelli MP, Carriero MV, et al. Human urokinase receptor concentration in malignant and benign breast tumours by in vitro quantitative autoradiography: comparison with urokinase levels1. Cancer Res 1993; 53: 3198-206.
27. Carriero MV, Franco P, Del Vecchio S, et al. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 1994; 54: 5445-54.
28. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004; 37: 541-48.
29. Nielsen BS, Sehested M, Duun S, et al. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 2001; 81: 1485-501.
30. List K, Jensen ON, Bugge TH, et al. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen- deficient mice. Biochemistry 2000; 39: 508-15.
31. Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985; 82: 4939-43.
32. Buko AM, Kentzer EJ, Petros A, Menon G, Zuiderweg ER, Sarin VK. Characterization of a posttranslational fucosylation in the growth factor domain of urinary plasminogen activator. Proc Natl Acad Sci USA 1991; 88: 3992-96.
33. Franco P, Iaccarino C, Chiaradonna F, et al. Phosphorylation of pro-urokinase at Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adhesion and motility. J Cell Biol 1997; 137: 779-91.
34. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11: 23-36.
35. Spraggon G, Phillips C, Nowak UK, et al. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure 1995; 3: 681-91.
36. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985; 100: 86-92.
37. Huai Q, Mazar AP, Kuo A, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006; 311: 656-9.
38. Klein DE, Stayrook SE, Shi F, Narayan K, Lemmon MA. Structural basis for EGFR ligand sequestration by Argos. Nature 2008; 453: 1271-5.
39. Appella E, Robinson EA, Ullrich, SJ, et al. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 1985; 262: 4437-40.
40. Magdolen V, Rettenberger P, Koppitz M, et al. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur J Biochem 1996; 237: 743-51.
41. Wilhelm OG, Wilhelm S, Escott GM, et al. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol 1999; 180: 225-35.
42. Pyke C, Eriksen J, Solberg H, et al. An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator. FEBS Lett 1993; 326: 69-74.
43. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003; 22: 205-22.
44. Selleri C, Montuori N, Ricci P, et al. In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer. Cancer Res 2006; 66: 10885-90.
45. Lin L, Gårdsvoll H, Huai Q, Huang M, Ploug M. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem 2010; 285: 10982-92.
46. Connolly BM, Choi EY, Gårdsvoll H, et al. Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Blood 2010; 116: 1593-603.
47. Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost 2007; 5 (Suppl 1): 24-31.
48. Franco P, Vocca I, Carriero MV, et al. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin. J Cell Sci 2006; 119: 3424-34.
49. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor- bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266: 12752-8.
50. Alfano D, Franco P, Vocca I, et al. The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost 2005; 93: 205-11.
51. Carriero MV, Del Vecchio S, Capozzoli M, et al. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 1999; 59: 5307-14.
52. Magdolen V, Bürgle M, de Prada NA, et al. Cyclo19,31[D-Cys19]- uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol Chem 2001; 382: 1197-205.
53. Rabbani SA, Gladu J, Mazar AP, Henkin J, Goltzman D. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. J Cell Physiol 1997; 172: 137-45.
54. Ploug M, Østergaard S, Gårdsvoll H, et al. Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001; 40: 12157-68.
55. Resnati M, Guttinger M, Valcamonica S, Sidenius S, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996; 15: 1572-82.
56. Bifulco K, Longanesi-Cattani I, Gargiulo L, et al. An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor. FEBS Lett 2008; 582: 1141-6.
57. Carriero MV, Longanesi-Cattani I, Bifulco K, et al. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. Mol Cancer Ther 2009; 9: 2708-17.
58. Kugler MC, Wei Y, Chapman HA. Urokinase receptor and integrin interactions. Curr Pharm Des 2003; 9: 1565-74.
59. Degryse B, Resnati M, Czekay RP, Loskutoff DJ, Blasi F. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J Biol Chem 2005; 280: 24792-803.
60. Patthy L. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 1985; 41: 657-63.
61. Li X, Bokman AM, Llinàs M, Smith RA, Dobson CM. Solution structure of the kringle domain from urokinase-type plasminogen activator. J Mol Biol 1994; 235: 1548-59.
62. Liu M, Zhang S. A kringle-containing protease with plasminogen- like activity in the basal chordate Branchiostoma belcheri. Biosci Rep 2009; 29: 385-95.
63. Stephens RW, Bokman AM, Myöhänen HT, et al. Heparin binding to the urokinase kringle domain. Biochemistry 1992; 31: 7572-79.
64. Bdeir K, Kuo A, Sachais BS, et al. The kringle stabilizes urokinase binding to the urokinase receptor. Blood 2003; 102: 3600-8.
65. Tarui T, Akakura N, Majumdar M, et al. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb Haemost 2006; 95: 524-34.
66. Pluskota E, Soloviev DA, Bdeir K, Cines DB, Plow EF. Integrin (alpha)M(beta)2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem 2004; 279: 18063-72.
67. Mukhina S, Stepanova V, Traktouev D, et al. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis. J Biol Chem 2000; 275: 16450-8.
68. Wang XQ, Bdeir K, Yarovoi S, Cines DB, Fang W, Abraham E. Involvement of the urokinase kringle domain in lipopolysaccharide- induced acute lung injury. J Immunol 2006; 177: 5550-7.
69. Franco P, Massa O, Garcia-Rocha M, et al. Protein kinase C- dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist. J Biol Chem 1998; 273: 27734-40.
70. Guo Y, Higazi AA, Arakelian A, et al. Peptide derived from the non receptor binding region of urokinase plasminogen activator (uPA) inhibits tumour progression and angiogenesis and induces tumour cell death in vivo. FASEB J 2000; 14: 1400-10.
71. Kim KS, Hong YK, Joe YA, et al. Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells. J Biol Chem 2003; 278: 11449-51.
72. Kim CK, Hong SH, Joe YA, Shim BS, Lee SK, Hong YK. The recombinant kringle domain of urokinase plasminogen activator inhibits in vivo malignant glioma growth. Cancer Sci 2007; 98: 253-8.
73. Kim CK, Joe YA, Lee SK, et al. Enhancement of anti-tumour activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model. Cancer Lett 2010; 288: 251-60.
74. Vocca I, Franco P, Alfano D, et al. Inhibition of migration and invasion of carcinoma cells by urokinase-derived antagonists of alphavbeta5 integrin activation. Int J Cancer 2009; 124: 316-25.
75. Guo Y, Mazar AP, Lebrun J, Rabbani SA. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumour growth and metastasis in a syngeneic model of breast cancer. Cancer Res 2002; 62: 4678-84.
76. Mishima K, Mazar AP, Gown A, et al. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci USA 2000; 97: 8484-9.
77. McGuire PG, Jones TR, Talarico N, Warren E, Das A. The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A6 suggests a new therapeutic target. Invest Ophthalmol Vis Sci 2003; 44: 2736-42.
78. Navaratna D, Menicucci G, Maestas J, Srinivasan R, McGuire P, Das AA. Peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes. FASEB J 2008; 22: 3310-7.
79. Berkenblit A, Matulonis UA, Kroener JF, et al. A6, an urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol 2005; 99: 50-7.
80. Ghamande SA, Silverman MH, Huh W, et al. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol 2008; 111: 89-94.
81. van der Voort R, Taher TE, Derksen PW, Spaargaren M, van der Neut R, Pals ST. The hepatocyte growth factor/Met pathway in development, tumourigenesis, and B-cell differentiation. Adv Cancer Res 2000; 79: 39-90.
82. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 2002; 277: 46932-9.
83. Carmeliet P, Moons L, Lijnen R, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17: 439-44.
84. Rømer MU, Kirkebjerg DA, Knud Larsen J, et al. Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis. Thromb Haemost 2005; 94: 859-66.
85. Romer J, Bugge TH, Pyke C, et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996; 2: 287-92.
86. Schuster V, Hügle B, Tefs K. Plasminogen deficiency. J Thromb Haemost 2007; 12: 2315-22.
87. Ke SH, Coombs GS, Tachias K, Corey DR, Madison EL. Optimal subsite occupancy and design of a selective inhibitor of urokinase. J Biol Chem 1997; 272: 20456-62.
88. Zeslawska E, Schweinitz A, Karcher A, et al. Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design. J Mol Biol 2000; 301: 465-75.
89. Schweinitz A, Steinmetzer T, Banke IJ, et al. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004; 279: 33613-22.
90. Setyono-Han B, Sturzebecher J, Schmalix WA, et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor wx-uk1. Thromb Haemost 2005; 93: 779-86.
91. Zhu M, Gokhale VM, Szabo L, et al. Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol Cancer Ther 2007; 6: 1348-56.
92. Heinemann V, Ebert MP, Pinter T, Bevan P, Neville NG, Mala C. Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Onc 2010; 28: 4060.
93. Hansen M, Wind T, Blouse GE, et al. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition. J Biol Chem 2005; 280: 38424-37.
94. Zhao G, Yuan C, Wind T, Huang Z, Andreasen PA, Huang M. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. J Struct Biol 2007; 160: 1-10.
95. Andersen LM, Wind T, Hansen HD, Andreasen PA. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: Changing species specificity by substitution of a single residue. Biochem J 2008; 412: 447-57.
96. Kobayashi H, Suzuki M, Hirashima Y, Terao T. The protease inhibitor bikunin, a novel anti-metastatic agent. Biol Chem 2003; 384: 749-54.
97. Fabbrini MS, Rappocciolo E, Carpani D, et al. Characterization of a saporin isoform with lower ribosome-inhibiting activity. Biochem J 1997; 322: 719-27.
98. Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001; 276: 17976-84.
99. Su Y, Ortiz J, Liu S, et al. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumour in athymic nude mice. Cancer Res 2007; 67: 3329-36.